Kopran's Khopoli formulation facility concludes EU GMP inspection with no critical observations
Kopran Ltd's formulation manufacturing facility at Khopoli concluded a Medicine Authority European Union (EU)-conducted GMP inspection on September 23, 2026 with no critical observations.
By ScoutQuest · · 1 min read
- Inspection
- Medicine Authority European Union (EU)-conducted GMP inspection concluded on September 23, 2026
- Critical Observations
- no critical observations
- Major Observations
- one major observation and some minor observations
- Release
- Press release
📌 The company says no data integrity related observations were raised during the inspection.
📌 Kopran says it is in the process to submit the compliance responses to the EU authorities within a fortnight.
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.